))
Behind the Science: CEO of ScanCell, Lindy Durrant on the Company's Breakthrough Antibody Evaluation
Manage episode 438041099 series 3502513
Kandungan disediakan oleh Karl West. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Karl West atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.
In this episode of the All Points West podcast, we sit down with Lindy Durrant, the founder and CEO of AIM-listed ScanCell. Since co-founding ScanCell in 1997, Lindy has been at the forefront of developing groundbreaking immunotherapies for cancer and infectious diseases. With over 25 years of experience in translational research, she has played a pivotal role in bringing monoclonal antibodies and cancer vaccines from the lab to clinical trials. We discuss the rapidly growing immuno-oncology market, the potential of ScanCell's GlyMab platform, and what the future holds for cancer treatment.
29 episod
Kongsi
